Why Gilead can’t stop talking about its ambitions in immunology

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.

Speaking at recent investor conferences, Gilead Sciences’ top executives have been emphatically bullish about the biotech’s years-long push to develop drugs for inflammatory and autoimmune diseases.

“It’s one of the three scientific areas that are our core focus,” Gilead Chief Financial Officer Andy Dickinson told investors at the Cantor Global Healthcare Conference earlier this month. “We’re the largest virology company. We’ve built a robust oncology business. The third leg of the stool, so to speak, is the I&I [inflammation and immunology] business that we’re growing.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe